Supernus Pharmaceuticals Downgraded to “Neutral” at Zacks (SUPN)
Supernus Pharmaceuticals (NASDAQ:SUPN) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, American Banking & Market News reports. They currently have a $8.80 target price on the stock. Zacks‘ price objective indicates a potential upside of 7.06% from the stock’s previous close.
Shares of Supernus Pharmaceuticals (NASDAQ:SUPN) traded down 0.24% during mid-day trading on Wednesday, hitting $8.20. The stock had a trading volume of 193,882 shares. Supernus Pharmaceuticals has a 52-week low of $4.45 and a 52-week high of $9.05. The stock’s 50-day moving average is $7.44 and its 200-day moving average is $6.93. The company’s market cap is $277.5 million.
Supernus Pharmaceuticals (NASDAQ:SUPN) last released its earnings data on Tuesday, November 12th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by $0.11. The company had revenue of $1.26 million for the quarter, compared to the consensus estimate of $2.54 million. The company’s revenue for the quarter was up 1328.6% on a year-over-year basis. Analysts expect that Supernus Pharmaceuticals will post $-2.33 EPS for the current fiscal year.
A number of other firms have also recently commented on SUPN. Analysts at FBR & Co. initiated coverage on shares of Supernus Pharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Supernus Pharmaceuticals in a research note to investors on Wednesday, October 30th. They set an “outperform” rating and a $12.00 price target on the stock. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. Supernus Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $11.36.
Supernus Pharmaceuticals, Inc (NASDAQ:SUPN) is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.